None, P. K., None, M. Y., None, A. M. & None, A. (2026). Aplastic Anemia in Pregnancy: Insights into Clinical Challenges and Outcomes—A Systematic Review. Journal of Contemporary Clinical Practice, 12(11), 422-431.
MLA
None, Priyanka Kumari, et al. "Aplastic Anemia in Pregnancy: Insights into Clinical Challenges and Outcomes—A Systematic Review." Journal of Contemporary Clinical Practice 12.11 (2026): 422-431.
Chicago
None, Priyanka Kumari, Medha Yadav , Anu Meena and Anchal . "Aplastic Anemia in Pregnancy: Insights into Clinical Challenges and Outcomes—A Systematic Review." Journal of Contemporary Clinical Practice 12, no. 11 (2026): 422-431.
Harvard
None, P. K., None, M. Y., None, A. M. and None, A. (2026) 'Aplastic Anemia in Pregnancy: Insights into Clinical Challenges and Outcomes—A Systematic Review' Journal of Contemporary Clinical Practice 12(11), pp. 422-431.
Vancouver
Priyanka Kumari PK, Medha Yadav MY, Anu Meena AM, Anchal A. Aplastic Anemia in Pregnancy: Insights into Clinical Challenges and Outcomes—A Systematic Review. Journal of Contemporary Clinical Practice. 2026 Nov;12(11):422-431.
Background: Aplastic anaemia (AA) in pregnancy is a rare bone marrow failure disorder associated with diagnostic challenges, therapeutic uncertainty and potentially serious maternal–fetal complications. This review systematically evaluates maternal, fetal and neonatal outcomes while providing a narrative overview of clinical challenges and evolving therapeutic strategies. PubMed/MEDLINE, Embase (Ovid), Cochrane CENTRAL and Google Scholar were searched for observational studies published between January 2016 and October 2026. Six eligible studies were included in a descriptive synthesis, while additional literature informed the discussion of diagnosis and management. The included studies reported substantial maternal morbidity, particularly haemorrhagic complications and transfusion requirements, alongside adverse fetal and neonatal outcomes, including prematurity and impaired fetal growth. Maternal haematological status and disease activity were associated with adverse outcomes in several cohorts, although methodological heterogeneity limited comparisons and precluded meta-analysis. From a therapeutic perspective, transfusion support remains fundamental, while ciclosporin has the most substantial pregnancy-specific experience among disease-directed treatments. Evidence supporting antenatal use of antithymocyte globulin and eltrombopag remains insufficient. These findings highlight the importance of multidisciplinary management, individualised therapeutic decisions and further pregnancy-specific research to improve maternal–fetal outcomes
Keywords
Aplastic anaemia
Pregnancy
Immunosuppressive therapy
Ciclosporin
Eltrombopag
Maternal–fetal outcomes.
INTRODUCTION
Aplastic anaemia (AA) is a rare, potentially life-threatening bone marrow failure disorder characterised by pancytopenia and hypocellular marrow, usually arising from immune-mediated destruction of haematopoietic stem and progenitor cells [1,2]. Pregnancy complicates diagnosis because physiological haematological changes may mask early cytopenias, while severe marrow failure increases the risks of haemorrhage, infection and adverse obstetric outcomes [3,4]. Whether pregnancy precipitates AA, exacerbates pre-existing disease or merely coincides with its presentation remains uncertain [3].
Management is challenging because maternal haematological stability must be balanced against fetal safety in the absence of robust pregnancy-specific therapeutic evidence. Transfusion support remains central but may not provide adequate disease control in women with progressive cytopenias [2,4]. Ciclosporin has the most substantial pregnancy-specific experience among disease-directed therapies for aplastic anaemia, although much of its fetal safety evidence is extrapolated from pregnancies in solid-organ transplant recipients [2,5,6]. Antithymocyte globulin is established outside pregnancy, while eltrombopag has expanded therapeutic options; however, their antenatal efficacy, fetal safety and optimal timing remain insufficiently established [2,7,8].
Uncertainty also extends to disease progression, treatment response and postpartum recovery. This narrative review examines diagnostic and management challenges, evolving therapeutic strategies and maternal–fetal outcomes, emphasising evidence gaps and individualised clinical decision-making.
MATERIALS AND METHODS
Search strategy: A literature search was conducted using PubMed/MEDLINE, Embase (Ovid), Cochrane CENTRAL and Google Scholar for studies published between January 2016 and October 2026. Search terms combined “aplastic anaemia,” “aplastic anemia” and pregnancy-related terms. Reference lists of relevant publications were also screened.
Eligibility criteria: Original observational studies reporting maternal, fetal or neonatal outcomes in pregnancies complicated by aplastic anaemia (AA) were considered eligible. Case reports, reviews, guidelines, conference abstracts without full-text publications and studies without extractable AA-specific pregnancy outcomes were excluded from the primary evidence synthesis.
Study selection and data extraction: Records were screened by title and abstract, with further assessment of potentially eligible reports. Data on study design, patient characteristics, clinical management and maternal–fetal outcomes were extracted. Six primary observational studies were summarised in Table 1.
Data synthesis: Findings were synthesised descriptively because of heterogeneity in study populations, management and outcomes. No independent meta-analysis was performed. Additional relevant literature, including historical studies, case reports, reviews, guidelines and evidence from nonpregnant populations, was used to support discussions of diagnostic challenges, therapeutic strategies and clinical management elsewhere in the manuscript.
The selection process for studies included in the systematic outcome synthesis is illustrated in Figure 1.
Clinical course of aplastic anaemia in pregnancy
The clinical course of aplastic anaemia during pregnancy is heterogeneous, encompassing de novo presentation, persistence of pre-existing disease and relapse following haematological remission [9–11]. Disease activity may remain stable or deteriorate, with worsening cytopenias and increasing transfusion requirements [9,10]. Lower maternal haemoglobin and platelet counts have been associated with increased obstetric complications [9,12]. Severe thrombocytopenia, marked bone marrow hypocellularity and later diagnosis during pregnancy have also been associated with poorer maternal outcomes in observational analyses [13]. However, differences in baseline disease severity, treatment history and inconsistent reporting of haematological outcomes limit comparisons across studies [10,14]. Distinguishing newly diagnosed AA from pre-existing disease and relapse is therefore important for interpreting clinical outcomes and informing individualised maternal surveillance.
Diagnostic challenges
Recognition of aplastic anaemia (AA) during pregnancy is complicated by physiological changes in blood counts. Expansion of maternal plasma volume lowers haemoglobin concentration, while platelet counts may decline with advancing gestation [15,16]. Consequently, early anaemia or thrombocytopenia may be attributed to pregnancy, delaying investigation of marrow failure [3]. Clinical manifestations reflect the affected cell lines: fatigue, bleeding and recurrent infections correspond to anaemia, thrombocytopenia and neutropenia, respectively [17]. In contrast to isolated mild cytopenias, persistent abnormalities affecting multiple cell lines, particularly with reticulocytopenia, should raise suspicion of AA [2]. A case reported by Del Pozzo et al. highlights the value of investigating unexplained third-trimester blood-count abnormalities [18].
Diagnostic evaluation begins with peripheral blood counts and reticulocyte assessment. AA is suspected when at least two of the following are present: haemoglobin <100 g/L, platelets <50 × 10⁹/L or neutrophils <1.5 × 10⁹/L [2]. Because pregnancy has several haematological mimics, investigations should exclude iron, folate and vitamin B12 deficiencies [16], along with gestational and immune thrombocytopenia [19,20]. Thrombotic microangiopathies, including thrombotic thrombocytopenic purpura and pre-eclampsia/HELLP syndrome, also warrant consideration where suggested by clinical and laboratory findings [21].
Confirmation requires demonstration of a hypocellular bone marrow after exclusion of alternative causes [2]. Bone marrow aspiration and trephine biopsy remain central, although profound thrombocytopenia warrants assessment and mitigation of procedural bleeding risk [2,3]. Pregnancy itself is not a contraindication to bone marrow examination, and clinically indicated investigation should not be unnecessarily delayed [22]. As hypocellularity is not specific to acquired AA, differentiation from hypoplastic myelodysplastic syndromes and inherited marrow failure disorders may require cytogenetic or molecular investigations in selected patients. Evaluation should also include screening for a paroxysmal nocturnal haemoglobinuria clone and assessment for secondary causes [2].
Severity and classification
The severity of aplastic anaemia (AA) is determined by bone marrow cellularity and peripheral blood count thresholds [2]. Severe AA (SAA) requires marrow cellularity <25%, or 25–50% with <30% residual haematopoietic cells, together with at least two of the following: neutrophils <0.5 × 10⁹/L, platelets <20 × 10⁹/L, or absolute reticulocytes <60 × 10⁹/L using automated counting. Very severe AA (VSAA) meets SAA criteria but has neutrophils <0.2 × 10⁹/L; confirmed cases that do not meet either definition are classified as non-severe AA (NSAA) [2].
Although these categories guide initial assessment, a single severity classification may not reflect changing clinical risk throughout gestation. Pregnancy may coincide with worsening cytopenias or relapse, without evidence establishing a causal relationship [3,4]. Progression from NSAA to SAA has been documented in an observational pregnancy cohort [12]. Accordingly, serial blood-count trends, transfusion requirements and clinical complications should complement severity classification when determining surveillance intensity and considering treatment escalation [2,4].
Management challenges during pregnancy
Management of aplastic anaemia during pregnancy requires balancing maternal haematological stability with fetal wellbeing as the disease and gestation progress. Beyond baseline severity, the trajectory of cytopenias, transfusion requirements and haemorrhagic or infectious complications may alter the risk–benefit assessment for treatment [2,4]. Earlier reports advocated considering pregnancy termination for severe disease presenting early in gestation and supportive care until delivery for later presentations [23]. These historical recommendations arose from limited case experience and should not be interpreted as universal contemporary practice. Subsequent observational experience demonstrated favourable maternal and neonatal outcomes with transfusion-based management in selected patients [24]; however, these findings do not establish its adequacy in progressive or refractory disease.
An important unresolved clinical question is when supportive treatment should be escalated to disease-directed therapy. Pregnancy-specific evidence does not establish validated escalation thresholds or the optimal timing of immunosuppressive treatment [2,4]. Decisions should therefore incorporate haematological trends, the effectiveness and burden of transfusion support, gestational age and maternal–fetal risks, with coordinated input from haematology, obstetrics, maternal–fetal medicine, anaesthesia and transfusion services [4] (Figure 2).
Supportive care and transfusion therapy
Red-cell and platelet transfusions are the cornerstone of supportive management of aplastic anaemia (AA) during pregnancy, maintaining oxygen-carrying capacity and haemostasis without correcting the underlying marrow failure. The 2024 British Society for Haematology guideline recommends maintaining platelet counts above 20 × 10⁹/L during pregnancy [2], while a haemoglobin target of approximately 8 g/dL reflects commonly reported supportive practice rather than a universally validated threshold [4]. These targets should be individualised according to maternal symptoms, bleeding, infection and anticipated obstetric procedures [2,4]. Favourable maternal and neonatal outcomes have been reported with transfusion-based management in selected pregnancies [24], although historical reports describe variable outcomes [23]. Severe thrombocytopenia has been associated with increased transfusion requirements and obstetric complications [25]. Contemporary cohorts also report differing transfusion needs between de novo and previously diagnosed AA, although underlying differences in disease severity and treatment exposure limit direct comparisons [10]. An isolated report of successful pregnancy despite refusal of blood products illustrates individualised care but does not establish the safety of withholding indicated transfusions [26].
Despite its essential role, prolonged transfusion support carries risks of HLA alloimmunisation, platelet refractoriness and iron overload, which may complicate subsequent haematological and peripartum management [4]. Concurrent severe neutropenia increases susceptibility to serious infections and necessitates close surveillance and prompt treatment [2]. Thus, supportive care requires ongoing assessment of blood-count trends, transfusion burden and clinical complications; progressive cytopenias or increasing transfusion requirements should prompt consideration of disease-directed therapy [2].
Immunosuppressive therapy
The principal therapeutic uncertainty in pregnancy-associated aplastic anaemia (AA) is how to balance the potential maternal benefits of immunosuppression against fetal exposure in the absence of comparative pregnancy-specific evidence. Ciclosporin has the most extensive antenatal experience among disease-directed agents and may be considered when clinically indicated under the 2024 British Society for Haematology guideline [2]. However, the broader pregnancy-safety literature is drawn largely from solid-organ transplant recipients [5,6]; reported prematurity and low birth weight cannot be confidently separated from the effects of maternal disease or concomitant treatment [6]. Reports involving ciclosporin and adjunctive corticosteroids or colony-stimulating factors provide limited pregnancy-associated AA evidence [21,27,28]. More recent observational data document haematological responses to ciclosporin in both de novo and pre-existing AA [10]. However, small, nonrandomly treated subgroups limit reliable attribution of these responses to treatment and assessment of their effects on obstetric outcomes.
This evidence gap is more pronounced for antithymocyte globulin (ATG). Although ATG combined with ciclosporin is established therapy for severe AA outside pregnancy [2,7], antenatal evidence remains insufficient to characterise maternal efficacy, fetal safety or longer-term offspring outcomes [21]. The 2024 guideline does not recommend ATG during pregnancy [2]. Contemporary observational evidence also describes postpartum ATG-based treatment [10]. However, these findings cannot be extrapolated to establish the safety of ATG administration during pregnancy. Consequently, the therapeutic dilemma extends beyond drug selection to the timing of intervention: deferring immunosuppression may avoid uncertain fetal exposure, yet progressive marrow failure may increase maternal risk. Treatment decisions must therefore remain individualised, without assuming that maternal haematological response necessarily translates into improved obstetric outcomes [2,21].
Eltrombopag and emerging treatment options
Eltrombopag, a thrombopoietin receptor agonist, has expanded treatment options for aplastic anaemia (AA) outside pregnancy by promoting multilineage haematopoietic recovery [8]. Its relevance to pregnancy-associated AA, however, raises a distinct evidentiary problem: established efficacy in nonpregnant patients does not establish either the benefit of antenatal exposure or fetal safety [2,8].
Pregnancy-specific evidence comprises isolated reports involving severe, refractory or non-severe AA [1,29,30]. Maternal haematological stability and successful deliveries have been reported, but concurrent treatment, transfusion support and the absence of comparison groups prevent reliable attribution of these outcomes to eltrombopag. These pregnancies have also been complicated by pre-eclampsia [30], fetal growth restriction or reduced late-gestational growth [1,29,30], and transient neonatal thrombocytopenia [1]. Such events cannot be causally attributed to eltrombopag, while successful deliveries cannot exclude uncommon or delayed adverse effects. A 2026 report of full-dose exposure throughout pregnancy further extends clinical experience; however, concomitant ciclosporin and transfusion support limit assessment of eltrombopag-specific efficacy [1]. Individual cases cannot establish optimal dosing, treatment timing or long-term offspring safety.
Indirect pregnancy data for thrombopoietin receptor agonists derive mainly from women with immune thrombocytopenia [31,32]. Although these reports provide limited information about maternal platelet responses and neonatal outcomes, differences in disease mechanisms and therapeutic objectives preclude direct extrapolation to the multilineage marrow failure of AA. Consistent with this uncertainty, the 2024 British Society for Haematology guideline does not recommend eltrombopag during pregnancy [2].
The unresolved question is whether any attributable and sustained maternal haematological benefit can justify uncertain fetal exposure and translate into improved obstetric outcomes. Pregnancy-specific studies linking treatment exposure, multilineage response and longer-term offspring outcomes are needed before an antenatal role can be defined.
Haematopoietic stem-cell transplantation
Allogeneic haematopoietic stem-cell transplantation (HSCT) is a potentially curative treatment for severe aplastic anaemia (AA). However, conditioning-related fetal toxicity and intensive immunosuppression generally preclude transplantation during pregnancy; when maternal haematological stability permits, definitive treatment is deferred until after delivery [2].
Evidence regarding HSCT in pregnancy-associated AA predominantly concerns treatment following pregnancy. Historical experience documented successful engraftment alongside graft rejection and fatal infectious complications [33], whereas a recent retrospective cohort of 18 patients reported 100% cumulative neutrophil and platelet engraftment, with overall and relapse/rejection-free survival of approximately 80% [34]. Although these findings support the feasibility of definitive treatment in pregnancy-associated AA, differences in patient selection and treatment practices limit direct comparisons across historical and contemporary cohorts. Importantly, these outcomes cannot be extrapolated to establish the safety of HSCT during gestation.
The principal clinical consideration is therefore the timing of definitive therapy in patients with persistent severe disease. Decisions regarding postpartum transplantation should consider maternal haematological stability, previous treatment response, donor availability and clinical recovery, with coordinated haematological and obstetric care [2,4].
Obstetric and peripartum management
Management of aplastic anaemia (AA) during the peripartum period requires close coordination between obstetric, haematological, anaesthetic and transfusion teams. Maternal haemoglobin and platelet counts have been associated with adverse pregnancy outcomes, although available observational data do not establish validated thresholds for predicting complications or determining delivery timing [9,12]. Clinical assessment should therefore consider trends in blood counts, bleeding or infectious complications, and fetal well-being throughout pregnancy [4].
The timing and mode of delivery should be determined primarily by obstetric indications, with vaginal delivery generally preferred when feasible [4]. Nevertheless, severe cytopenias require advance planning for haemorrhage, blood-product availability and potential operative intervention. Transfusion support should be individualised to the anticipated procedure and clinical condition rather than based solely on antenatal maintenance targets [4,21]. Anaesthetic planning is particularly challenging in patients with thrombocytopenia, as an AA-specific platelet threshold for safe neuraxial anaesthesia has not been established [4]. Decisions should incorporate platelet trends, additional haemostatic risks and the relative risks of alternative techniques [4].
Delivery does not necessarily resolve the underlying marrow failure. Persistent AA after pregnancies with a new diagnosis and variable postpartum recovery following relapse in previously treated patients have both been documented [35,36]. Continued haematological follow-up is therefore important to identify ongoing transfusion needs or indications for disease-directed therapy.
Maternal outcomes
Characteristics and reported maternal–fetal outcomes of the six included observational studies are summarised in Table 1.
Maternal morbidity in pregnancies complicated by aplastic anaemia (AA) encompasses haematological instability and obstetric complications, particularly haemorrhage, infection and hypertensive disorders [4,14]. A 2025 meta-analysis of seven studies involving 248 pregnancies reported pooled estimates of 13% for pre-eclampsia, 12% for postpartum haemorrhage, 74% for intrapartum transfusion and 55% for caesarean delivery; maternal mortality was approximately 4% [14]. The substantial transfusion burden reflects the clinical consequences of marrow failure, whereas delivery mode also depends on obstetric practice and case selection.
Maternal risk appears closely related to disease activity and the severity of cytopenias. Across observational cohorts, lower haemoglobin and platelet counts have been associated with complications [9,12]. The 2026 cohort of 65 pregnancies further identified active disease before delivery as associated with severe composite maternal–fetal outcomes [9]. Severe thrombocytopenia, marked marrow hypocellularity and later diagnosis have also been linked with poorer maternal outcomes in smaller studies [13,25]. Together, these findings support consideration of evolving haematological status in maternal risk assessment.
Historical series reported maternal deaths, particularly among women with severe disease [37,38]. By contrast, no maternal deaths occurred in the contemporary cohort despite considerable maternal–fetal morbidity [9]. This contrast suggests that favourable survival does not necessarily imply low morbidity, although differences between cohorts preclude attributing improved outcomes to specific treatments [9,14].
Fetal and neonatal outcomes
Fetal and neonatal complications associated with aplastic anaemia (AA) predominantly include pregnancy loss, impaired fetal growth and prematurity. In pooled analyses, spontaneous abortion, fetal growth restriction and intrauterine fetal death were reported in approximately 5%, 6% and 5% of pregnancies, respectively, while neonatal mortality approached 7% [14]. Historical reports established that successful pregnancy is possible despite maternal AA and described more favourable outcomes across successive treatment eras, although these observations cannot establish the contribution of individual interventions [11,39]. Prematurity nevertheless remains a prominent complication, with rates of 27.3% and 21% reported in separate cohorts [12,35]. Among pregnancies complicated by newly diagnosed AA, adverse fetal outcomes occurred in 24%, including three late-preterm births and one case of fetal growth restriction [10].
Neonatal morbidity extends beyond prematurity. In a contemporary cohort, preterm delivery, low birth weight and neonatal intensive care admission occurred in 53.3%, 23.3% and 53.3% of cases, respectively [40]. Maternal anaemia was independently associated with low birth weight, while maternal neutropenia and thrombocytopenia were associated with adverse neonatal outcomes [40]. Notably, another contemporary cohort reported no neonatal haematological abnormalities, suggesting that substantial perinatal morbidity can occur without detectable impairment of neonatal haematopoiesis [9].
Postpartum disease course and future pregnancies
The postpartum course of aplastic anaemia (AA) remains variable, and spontaneous haematological recovery following delivery cannot be assumed. In a North American series, none of the five pregnancies in which AA was first diagnosed showed spontaneous postpartum resolution [35]. Conversely, among previously immunosuppressed women who relapsed during pregnancy, some recovered spontaneously after delivery, whereas others required further treatment [36]. These observations suggest that postpartum recovery may differ according to disease history, although reliable predictors remain undefined. Continued haematological surveillance is therefore essential to assess persistent cytopenias, transfusion requirements and infectious complications. For patients with persistent severe disease, postpartum treatment decisions may include allogeneic haematopoietic stem-cell transplantation, supported by historical reports of transplantation after delivery and contemporary outcomes in selected patients with pregnancy-associated AA [33,34].
Successful pregnancy remains possible in women with AA, particularly during haematological remission, although subsequent pregnancies may be complicated by disease recurrence [4,11]. In a multicentre study of previously immunosuppressed women, relapse occurred in seven of 36 pregnancies (19%) [36]. These findings highlight the importance of preconception counselling, including assessment of disease status, previous treatment response, medication requirements and recurrence risk, followed by coordinated haematological and obstetric surveillance throughout pregnancy [4,11,36].
Interpretation and limitations of current evidence
Current evidence identifies substantial maternal, fetal and neonatal morbidity in pregnancies complicated by aplastic anaemia (AA), but does not clearly distinguish the consequences of marrow failure from those of its treatment. Pooled estimates provide a useful measure of reported complications; however, variation in disease severity, gestational age, supportive care and outcome definitions limits comparisons across cohorts [3,4,14].
Interpretation of therapeutic outcomes is further complicated by confounding by indication: patients selected for disease-directed treatment may have more severe or progressive cytopenias than those managed supportively. Consequently, improvement in haematological parameters cannot by itself demonstrate reduced obstetric or neonatal morbidity. This distinction is particularly important for ciclosporin and eltrombopag, for which pregnancy-specific efficacy and fetal safety remain inadequately characterised; experience derived from solid-organ transplantation or immune thrombocytopenia cannot substitute for AA-specific evidence [1,5,6,29–32].
The principal limitation is therefore the absence of comparable data linking treatment exposure, haematological response and clinically meaningful maternal–fetal outcomes. Current evidence supports individualised care but cannot establish the optimal timing or comparative benefit of disease-directed treatment.
CONCLUSIONS AND FUTURE DIRECTIONS
Aplastic anaemia (AA) in pregnancy requires a balance between maternal haematological stability and fetal safety, with management guided by disease severity, gestational age and the evolving clinical course. Supportive transfusion-based care remains central, while disease-directed treatment should be considered when maternal risk outweighs uncertainties surrounding fetal exposure. Although ciclosporin has comparatively greater pregnancy-related experience, evidence for antithymocyte globulin, eltrombopag and other emerging therapies remains insufficient to support routine antenatal use. Maternal, fetal and neonatal outcomes remain variable, and postpartum recovery cannot be assumed; these uncertainties reinforce the need for individualised multidisciplinary care.
Future research should move beyond documenting successful pregnancies or isolated haematological
responses to identify when supportive management should be escalated and whether disease-directed therapy improves clinically meaningful maternal and offspring outcomes. Prospective multicentre registries using standardised measures of disease severity, treatment timing and exposure, transfusion burden, haematological response and obstetric and neonatal outcomes are needed to address these questions. Longer-term follow-up should also assess postpartum recovery, relapse in subsequent pregnancies and offspring outcomes after antenatal treatment. Such data may support pregnancy-specific risk stratification, more informed counselling and evidence-based therapeutic decisions.
Key points
• Persistent cytopenias affecting multiple cell lines, particularly with reticulocytopenia, warrant investigation for aplastic anaemia rather than attribution to physiological haematological changes during pregnancy.
• Aplastic anaemia severity classification alone is insufficient for antenatal risk assessment; serial blood counts, transfusion requirements and bleeding or infectious complications should guide surveillance and treatment escalation.
• Red-cell and platelet transfusions remain the cornerstone of supportive care, but transfusion targets must be individualised, particularly when bleeding or invasive obstetric procedures are anticipated.
• Ciclosporin may be considered when disease-directed treatment is necessary, whereas current guidelines do not recommend routine antenatal use of antithymocyte globulin or eltrombopag because of insufficient pregnancy-specific evidence.
• Maternal haematological stability does not necessarily ensure favourable obstetric or neonatal outcomes, and delivery does not reliably lead to remission of aplastic anaemia.
• Small observational cohorts, heterogeneous treatment approaches and confounding by indication limit conclusions about therapeutic effectiveness, highlighting the need for prospective multicentre studies with standardised maternal and neonatal outcomes.
Authors’ contributions
• Priyanka Kumari: Conceptualized the review, conducted the literature review, and prepared the original manuscript draft.
• Medha Yadav: Conducted the literature review and critically reviewed and edited the manuscript.
• Anu Meena: Conducted the literature review and critically reviewed and edited the manuscript.
• Anchal: Critically reviewed and edited the manuscript.
• All authors read and approved the final version of the manuscript.
Conflict of interest
• The authors declare no conflicts of interest.
Source of funding
• The authors declare that no funding was received for this work.
Acknowledgments
• None.
• AI use statement
• ChatGPT (OpenAI) was used for language editing, spelling correction and manuscript formatting.
REFERENCES
1. Frey SM, Alashkar F, Reinhardt HC, Röth A. Successful treatment of aplastic anemia with eltrombopag during pregnancy: a short report. EJHaem. 2026;7(2):e70244. https://doi.org/10.1002/jha2.70244
2. Kulasekararaj A, Cavenagh J, Dokal I, Foukaneli T, Gandhi S, Garg M, et al. Guidelines for the diagnosis and management of adult aplastic anaemia: a British Society for Haematology guideline. Br J Haematol.2024;204(3):784-804. https://doi.org/10.1111/bjh.19236
3. Perolla A, Cela B, Semanaj V, Dedej-Kurti T, Caja T. Aplastic anaemia in pregnancy: a case-based comprehensive review of the literature. Cureus. 2024;16(4):e58365. https://doi.org/10.7759/cureus.58365
4. Riveros-Perez E, Hermesch AC, Barbour LA, Hawkins JL. Aplastic anemia during pregnancy: a review of obstetric and anesthetic considerations. Int J Womens Health. 2018;10:117-125. https://doi.org/10.2147/IJWH.S149683
5. McKay DB, Josephson MA. Pregnancy in recipients of solid organs—effects on mother and child. N Engl J Med.2006;354(12):1281-1293. https://doi.org/10.1056/NEJMra050431
6. Paziana K, Del Monaco M, Cardonick E, Moritz M, Keller M, Smith B, et al. Ciclosporin use during pregnancy. Drug Saf. 2013;36(5):279-294. https://doi.org/10.1007/s40264-013-0034-x
7. Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187-207. https://doi.org/10.1111/bjh.13853
8. Guo H, Liu C, Kang L, Liu C, Liu Y. Safety and efficacy of eltrombopag in patients with aplastic anemia: a systematic review and meta-analysis of randomized controlled trials. Hematology. 2024;29(1):2335419. https://doi.org/10.1080/16078454.2024.2335419
9. Wu X, Yang Z, Zhang X, Lu S, Sun A, Wu D, et al. Clinical features and maternal-fetal outcome of pregnancy with aplastic anaemia: a single-centre retrospective study. Br J Haematol. 2026;208:2222-2228. https://doi.org/10.1111/bjh.70464
10. Bortolotti M, Trikha R, Salter S, Large J, Vlachodimitropoulou E, Gandhi S, et al. Pregnancy in acquired bone marrow failure syndromes: antenatal management and maternal and fetal outcomes. Am J Hematol. 2024;99(8):1647-1650. https://doi.org/10.1002/ajh.27372
11. Pajor A, Kelemen E, Szakács Z, Lehoczky D. Pregnancy in idiopathic aplastic anemia (report of 10 patients). Eur J Obstet Gynecol Reprod Biol. 1992;45(1):19-25. https://doi.org/10.1016/0028-2243(92)90189-6
12. Bo L, Liang MY, Zhang Y, Wang SM, Zhang XH. Aplastic anemia associated with pregnancy: maternal and fetal complications. J Matern Fetal Neonatal Med. 2016;29(7):1120-1124. https://doi.org/10.3109/14767058.2015.1037733
13. Chen KJ, Chang YL, Chang H, Su SY, Peng HH, Chang SD, et al. Long-term outcome of pregnancy complicating with severe aplastic anemia under supportive care. Taiwan J Obstet Gynecol. 2017;56(5):632-635. https://doi.org/10.1016/j.tjog.2017.08.010
14. Arora A, Jain A, Lad D, Ganguly D, Khatri P, Shamim MA, et al. Maternal and fetal outcomes of aplastic anemia during pregnancy and delivery: systematic review and meta-analysis. Eur J Haematol. 2025;114:202-212. https://doi.org/10.1111/ejh.14317
15. Soma-Pillay P, Nelson-Piercy C, Tolppanen H, Mebazaa A. Physiological changes in pregnancy. Cardiovasc J Afr.2016;27(2):89-94. https://doi.org/10.5830/CVJA-2016-021
16. Patel P, Balanchivadze N. Hematologic findings in pregnancy: a guide for the internist. Cureus. 2021;13(5):e15149. https://doi.org/10.7759/cureus.15149
17. Stibbe KJM, Wildschut HIJ, Lugtenburg PJ. Management of aplastic anemia in a woman during pregnancy: a case report. J Med Case Rep. 2011;5:66. https://doi.org/10.1186/1752-1947-5-66
18. Del Pozzo J, Kouba I, Goldman T, Muscat J. Importance of the third trimester complete blood count: a case report on aplastic anemia in pregnancy. J Hematol. 2023;12(3):114-117. https://doi.org/10.14740/jh1131
19. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010 Jan 14;115(2):168-86. https://doi.org/10.1182/blood-2009-06-225565
20. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120(4):574-596. https://doi.org/10.1046/j.1365-2141.2003.04131.x
21. Patel PB, Patel N, Hedges MA, Benson AE, Tomer A, Lo JO, Shatzel JJ. Hematologic complications of pregnancy. Eur J Haematol. 2025;114(4):596-614. https://doi.org/10.1111/ejh.14372
22. Nanda S, Nana M, Nguyen-Hoang L, Adam S, McAuliffe F, Bergman L, et al. Cancer in pregnancy: FIGO best practice advice and narrative review. Int J Gynaecol Obstet. 2025;171(1):131-151. https://doi.org/10.1002/ijgo.70258
23. Aitchison RG, Marsh JC, Hows JM, Russell NH, Gordon-Smith EC. Pregnancy associated aplastic anaemia: a report of five cases and review of current management. Br J Haematol. 1989;73(4):541-545. https://doi.org/10.1111/j.1365-2141.1989.tb00294.x
24. Kwon JY, Lee Y, Shin JC, Lee JW, Rha JG, Kim SP. Supportive management of pregnancy-associated aplastic anemia. Int J Gynaecol Obstet. 2006;95(2):115-120. https://doi.org/10.1016/j.ijgo.2006.07.005
25. Shin JE, Lee Y, Kim SJ, Shin JC. Association of severe thrombocytopenia and poor prognosis in pregnancies with aplastic anemia. PLoS One. 2014;9(7):e103066. https://doi.org/10.1371/journal.pone.0103066
26. Jakiel G, Ciebiera M, Słabuszewska-Jóźwiak A, Horosz B, Bińkowska M, Wilińska M, et al. Successful obstetric and hematologic outcome of aplastic anemia in a pregnant Jehovah’s Witness. Int J Immunopathol Pharmacol.2016;29(3):543-548. https://doi.org/10.1177/0394632016656188
27. Rathore S, Pramanick A, Regi A, Lionel J. Aplastic anemia in pregnancy. J Obstet Gynaecol India. 2014;64(Suppl 1):26-28. https://doi.org/10.1007/s13224-013-0431-1
28. Thakral B, Saluja K, Sharma RR, Marwaha N, Malhotra P, Varma N, et al. Successful management of pregnancy-associated severe aplastic anemia. Eur J Obstet Gynecol Reprod Biol. 2007;131(2):244-245. https://doi.org/10.1016/j.ejogrb.2006.04.040
29. Suminaga Y, Chigusa Y, Kondo T, Okamoto H, Kawamura Y, Taki M, et al. Aplastic anemia treated with eltrombopag during pregnancy. Case Rep Obstet Gynecol. 2022;2022:5889427. https://doi.org/10.1155/2022/5889427
30. Kawabata I, Yokote R, Kasano S, Ogawa J, Kato M, Ichikawa T, et al. Preeclampsia in a pregnant woman with severe aplastic anemia: a case report. Clin Case Rep. 2022;10(12):e6789. https://doi.org/10.1002/ccr3.6789
31. Howaidi J, AlRajhi AM, Howaidi A, AlNajjar FH, Tailor IK. Use of thrombopoietin receptor agonists in pregnancy: a review of the literature. Hematol Oncol Stem Cell Ther. 2022;15(1):1-6. https://doi.org/10.1016/j.hemonc.2021.05.004
32. Michel M, Ruggeri M, Gonzalez-Lopez TJ, Alkindi S, Cheze S, Ghanima W, et al. Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study. Blood.2020;136(26):3056-3061. https://doi.org/10.1182/blood.2020007594
33. Doney K, Storb R, Buckner CD, Sanders J, Witherspoon R, Thomas ED. Marrow transplantation for treatment of pregnancy-associated aplastic anemia. Exp Hematol. 1985;13(10):1080-1083.
34. Li X, Wu L, Li Y, Mo W, Chen X, Zhou M, et al. Outcomes of allogeneic hematopoietic stem cell transplantation in pregnancy-associated aplastic anemia. Acta Haematol. 2026; published online March 13, 2026:1-14. https://doi.org/10.1159/000551296
35. McGowan KE, Malinowski AK, Schuh AC, Whittle W, Shehata N. Aplastic anaemia in pregnancy—a single centre, North American series. Br J Haematol. 2019;184(3):436-439. https://doi.org/10.1111/bjh.15654
36. Tichelli A, Socié G, Marsh J, Barge R, Frickhofen N, McCann S, et al. Outcome of pregnancy and disease course among women with aplastic anemia treated with immunosuppression. Ann Intern Med. 2002;137(3):164-172. https://doi.org/10.7326/0003-4819-137-3-200208060-00008
37. Choudhry VP, Gupta S, Gupta M, Kashyap R, Saxena R. Pregnancy associated aplastic anemia—a series of 10 cases with review of literature. Hematology. 2002;7(4):233-238. https://doi.org/10.1080/1024533021000024067
38. Deka D, Malhotra N, Sinha A, Banerjee N, Kashyap R, Roy KK. Pregnancy associated aplastic anemia: maternal and fetal outcome. J Obstet Gynaecol Res. 2003;29(2):67-72. https://doi.org/10.1046/j.1341-8076.2002.00077.x
39. Suda T, Omine M, Tsuchiya J, Maekawa T. Prognostic aspects of aplastic anemia in pregnancy. Experience on six cases and review of the literature. Blut. 1978;36(5):285-298. https://doi.org/10.1007/BF01880679
40. Ma J, Luo F, Yan L. Neonatal outcomes and related risk factors of 30 cases with aplastic anemia in pregnancy: a retrospective study. Early Hum Dev. 2023;185:105855. https://doi.org/10.1016/j.earlhumdev.2023.1058.
Recommended Articles
Original Article
Association of Perceived Academic Stress with Cardiac Autonomic Function Among Undergraduate Medical Students: A Heart Rate Variability Study
Clinical Efficacy and Adverse Effects of Intravitreal Triamcinolone Acetonide versus Bevacizumab on Macular Thickness and Visual Acuity in Patients with Diabetic Macular Edema